The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Atezolizumab with venetoclax and obinutuzumab in patients with CLL
Whilst atezolizumab, a PD-L1 checkpoint inhibitor, has only been approved in solid tumor indications, studies have suggested checkpoint inhibitors with venetoclax may have clinical benefit in patients with chronic lymphocytic leukemia (CLL). Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from a Phase II trial (NCT02846623) of venetoclax, obinutuzumab, and atezolizumab in patients with chronic lymphocytic leukemia. The regimen resulted in high rated of remission in bone marrow and had an acceptable safety profile. Whilst no patients have currently progressed, more follow up is required to accurately determine progression-free survival (PFS). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
